$50.60
Value $32.5B
GMAB and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$50.60
Value $32.5B
$339.85
Value $308B
Genmab A/S (GMAB) has a market value of $32.5B and UnitedHealth (UNH) $308B. Over the last year, with dividends, GMAB moved +65.5% and UNH +12.9%. The P/E is 33.8 for GMAB and 19.4 for UNH. Dividend yield: GMAB none, UNH 2.67%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
GMAB$32.5B
UNH$308B
UNH is 9.5 times GMAB
Revenue, 12 months
GMAB$3.7B
UNH$450B
UNH is 121 times GMAB
Net income, 12 months
GMAB$963M
UNH$15.9B
UNH is 16 times GMAB
Operating margin
GMAB28.6%
UNH5.3%
23.3 points apart
ROIC
GMAB7.8%
UNH11.3%
3.5 points apart
P/E
GMAB33.8
UNH19.4
GMAB is 1.7 times UNH
Dividend yield
GMAB0.0%
UNH2.7%
2.7 points apart
5-year return
GMAB+22.0%
UNH-15.4%
37.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
GMAB+22.0%
UNH-15.4%
| Period | GMABWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +65.5%Price +65.5% | +12.9%Price +10.0% |
| 3 years since November 20, 2023 | +55.9%+15.9% a yearPrice +55.9% | -32.4%-12.2% a yearPrice -36.5% |
| 5 years since November 19, 2021 | +22.0%+4.1% a yearPrice +22.0% | -15.4%-3.3% a yearPrice -22.8% |
| 10 years since November 21, 2016 | +177.1%+10.7% a yearPrice +177.1% | +166.8%+10.3% a yearPrice +125.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
GMABGenmab A/SUNHUnitedHealth
| Price | $50.60 | $339.85 |
|---|---|---|
| Market value | $32.5B | $308B |
| Enterprise value (EV) | $35.9B | $354B |
| P/E | 33.8 | 19.4 |
| P/E, 5-year median | 4.8 | 25.0 |
| P/B | 5.6 | 3.0 |
| EV/EBIT | 33.8 | 14.8 |
| Free cash flow yield | 3.5% | 7.4% |
| Revenue, 12 months | $3.7B | $450B |
|---|---|---|
| Net income, 12 months | $963M | $15.9B |
| Free cash flow, 12 months | $1.1B | $22.8B |
| Earnings per share, 12 months | $1.54 | $17.52 |
| Revenue growth, year on year | 19.2% | 11.8% |
| Revenue growth a year, past | +24.8%over 2 years | +11.7%over 5 years |
| EPS growth a year, past | -51.7%over 2 years | -3.8%over 5 years |
| Gross margin | 93.6% | 88.3% |
|---|---|---|
| Operating margin | 28.6% | 5.3% |
| Net margin | 25.9% | 3.5% |
| ROIC | 7.8% | 11.3% |
| ROE | 16.5% | 15.5% |
| Cash | $1.7B | $28.5B |
|---|---|---|
| Total debt | $5.2B | $74.3B |
| Net debt / EBITDA | – | 1.6 |
| Interest cover | 4.0× | 6.2× |
| Dividend yield | – | 2.7% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | 1.3% | 1.8% |
| Shareholder yield | 1.3% | 4.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($308B) is about 9.5 times Genmab A/S ($32.5B), at today's prices.
Since November 21, 2016, GMAB's price moved +177.1% and UNH's +125.9%. With dividends: GMAB +177.1% (+10.7% a year), UNH +166.8% (+10.3% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Genmab A/S and 2.67% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
At today's price, the P/E is 33.8 for GMAB and 19.4 for UNH. The median of the last five years was 4.8 and 25.0, which shows where each stands against its own past.
Over the last twelve months, the net margin was 25.9% for Genmab A/S and 3.5% for UnitedHealth, and the operating margin 28.6% and 5.3%. Revenue was $3.7B and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.